Kadkhodayan S, Homaee Shandiz F
Department of Obstetrics and Gynecology, Women's Health Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Radiotherapy Oncology, Research Center of Solid Tumor Treatment, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
J Med Life. 2015;8(Spec Iss 3):184-189.
The most common cancer is Breast Cancer and the first principal purpose of cancer deaths in females of 44-40 ages. The currency of three negative breast cancer involves 10-17%. his sort cancer of the breast is described by a negative receptor of estrogen, progesterone, and HER2 that is much more competitive than the other kinds and the forecast is weaker. Therefore, this research was conducted with the aim of evaluating the outcomes of the medication in patients with a triple negative sort of breast cancer about the different patients with breast cancer. This historical group research was conducted by leading to the reports of all patients with breast cancer whose medication and follow-up was conducted in Hospital of Mashhad Ghaem through 2001 and 2010, their ER, PR, HER2 outcomes being reported in the files. Based on immunohistochemical records (ER, PR, HER2), patients were split into 2 collections: triple negative and another negative and the therapeutic results were analyzed among the 2 groups regarding two and five-year disease-free and throughout durability by Kaplan-Meier method. P<0.05 was regarded necessary. The medicinal studies of 331 cases with breast cancer were investigated in this research. The number of members in the Triple negative collection was 101 (30.5%) and in another negative group was 230 (69.5%). The base overall durability in the triple negative was 32.48 ± 24.56 months and in another negative was 29.67 ± 22.36 months and no notable variation was recognized in the studied collections (P=0.306). Furthermore, the low disease-free durability in the triple negative group was 30.57 ± 24.56 months and in another negative was 28.21 ± 21.72 months and no important variation was recognized in the studied collections (P=0.184). under previously directed investigations, between all the samples of breast cancer, Triple negative had a weaker forecast and a lower durability with the cases in our research, the overall durability and disease-free longevity got were the same in 2 collections of Triple negative and another negative, and the basis of this relationship was apparently the residence of HER2 + subgroup in the non-Triple negative collection which pointed to the durability of cases in the non-Triple negative collection be similar to the Triple negative collection.
最常见的癌症是乳腺癌,也是40至44岁女性癌症死亡的首要主要原因。三阴性乳腺癌的发生率为10%至17%。这种类型的乳腺癌表现为雌激素、孕激素和HER2受体阴性,比其他类型更具侵袭性且预后较差。因此,本研究旨在评估三阴性乳腺癌患者与其他不同类型乳腺癌患者的药物治疗效果。这项历史性队列研究通过查阅2001年至2010年在马什哈德加姆医院接受药物治疗和随访的所有乳腺癌患者的报告进行,其雌激素受体(ER)、孕激素受体(PR)、HER2结果均记录在案。根据免疫组化记录(ER、PR、HER2),患者被分为两组:三阴性组和其他阴性组,并采用Kaplan-Meier法分析两组患者的两年和五年无病生存率及总生存期。P<0.05被视为有统计学意义。本研究调查了331例乳腺癌患者的药物治疗情况。三阴性组有101例(30.5%),其他阴性组有230例(69.5%)。三阴性组的总生存期为32.48±24.56个月,其他阴性组为29.67±22.36个月,两组间无显著差异(P=0.306)。此外,三阴性组的无病生存期为30.57±24.56个月,其他阴性组为28.21±21.72个月,两组间也无显著差异(P=0.184)。在既往的研究中,在所有乳腺癌样本中,三阴性乳腺癌的预后较差且生存期较短,但在我们的研究中,三阴性组和其他阴性组的总生存期和无病生存期相同,这种关系的基础显然是非三阴性组中HER2+亚组的存在,这表明非三阴性组患者的生存期与三阴性组相似。